Navigation Links
DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
Date:7/27/2009

CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
2. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
3. DURECT to Participate in Cowen and Company Healthcare Conference
4. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
5. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
6. DURECT Corporation to Participate in Upcoming Healthcare Conferences
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
9. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
10. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
11. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... ... 28, 2017 , ... The Radiology Business Management Association (RBMA) is ... its new executive director. Mr. Still was selected through a careful months-long search by ... he is known to our members, has been a part of building the RBMA ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group ... serving as new board chair for Orange County health care system CalOptima Friday. ... of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... STRASBOURG, France and TEL AVIV, Israel ... opening a subsidiary in Israel . This new ... , will be mostly dedicated to research and development of novel ... Emosis Ltd will also, when relevant, locally support commercialization and sales ... ...
(Date:3/28/2017)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ... other unmet medical needs, announced today two poster ... annual meeting.  The first poster to be presented ... ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer ... presented on April 4 is entitled " Kinase ...
(Date:3/28/2017)... The global flow cytometry ... by 2025, according to a new study by Grand ... and cancer is expected to upsurge the demand for ... coming years. In addition, higher number of physicians is ... cell therapy, due to adverse effects caused by chemotherapy ...
Breaking Medicine Technology: